Enliven Therapeutics Inc
(ELVN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2001 | 12-2000 | 09-2000 | 06-2000 | 03-2000 | |
| Assets | |||||
| Current Assets | |||||
| Other current assets | 1,520 | 1,220 | 1,160 | 2,960 | 2,530 |
| TOTAL | $1,520 | $1,220 | $1,160 | $2,960 | $2,530 |
| Non-Current Assets | |||||
| PPE Net | 6,040 | 6,660 | 7,300 | 13,130 | 14,040 |
| Investments And Advances | 0 | 0 | 290 | 1,510 | 3,450 |
| Other Non-Current Assets | 1,170 | 1,230 | 90 | 90 | 110 |
| TOTAL | $7,210 | $7,890 | $7,680 | $14,730 | $17,600 |
| Total Assets | $8,730 | $9,110 | $8,840 | $17,690 | $20,130 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,370 | 2,620 | 4,210 | 3,620 | 3,480 |
| Accrued Expenses | 11,140 | 11,610 | 12,690 | 10,750 | 11,520 |
| Other current liabilities | 13,710 | 12,700 | 13,000 | 12,640 | 17,660 |
| TOTAL | $27,220 | $26,930 | $29,900 | $27,010 | $32,660 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 3,080 | 3,280 | 0 | 0 | 0 |
| TOTAL | $5,340 | $5,830 | $4,500 | $1,690 | $1,690 |
| Total Liabilities | $32,560 | $32,760 | $34,400 | $28,700 | $34,350 |
| Shareholders' Equity | |||||
| Common Shares | 10 | 10 | 10 | 10 | 10 |
| Other shareholders' equity | 620 | 500 | 30 | -40 | -43 |
| TOTAL | $77,300 | $76,960 | $76,090 | $75,870 | $75,527 |
| Total Liabilities And Equity | $109,860 | $109,720 | $110,490 | $104,570 | $109,877 |